Multiple Myeloma Clinical Trials

• Vaccine Therapy Plus GM-CSF in Treating Patients With Multiple Myeloma Undergoing Bone Marrow or Peripheral Stem Cell Transplantation
  ClinicalTrials.gov Identifier: NCT00002787 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Combination Chemotherapy and Interferon alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma
  ClinicalTrials.gov Identifier: NCT00002599 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Bortezomib and Liposomal Doxorubicin in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00088855 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00004903 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Bortezomib in Combination with CC-5013 in Patients with Relapsed/Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00153933 - Active, not recruiting
  Refractory Multiple Myeloma; Relapsed Multiple Myeloma; Multiple Myeloma
  
• Combination Chemotherapy With or Without Interferon alfa in Treating Patients With Previously Untreated Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00002556 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00003490 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Combination Chemotherapy in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00002678 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00098475 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Dexamethasone With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00064038 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00006184 - Recruiting
  Multiple Myeloma
  
• Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
  ClinicalTrials.gov Identifier: NCT00002850 - Recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; Infection
  
• Melphalan, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00003954 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Combination Chemotherapy With or Without Thalidomide in Treating Patients With Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00005834 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Phase III Randomized Study of Melphalan With or Without Holmium Ho 166 DOTMP Followed By Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00008229 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Thalidomide and Prednisone After Autologous Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00049673 - Recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant
  ClinicalTrials.gov Identifier: NCT00048464 - Active, not recruiting
  Multiple Myeloma
  
• Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00017602 - Active, not recruiting
  refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Melphalan and Prednisone With or Without Bortezomib in Treating Older Patients With Newly Diagnosed Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00109902 - Recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00003603 - Active, not recruiting
  refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00124579 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00005792 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients with Relapsed Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00080405 - Active, not recruiting
  Multiple Myeloma
  
• Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00040937 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00006219 - Active, not recruiting
  Multiple Myeloma
  
• Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00114101 - Recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00006890 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00014508 - Active, not recruiting
  refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients with Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00095680 - Active, not recruiting
  Multiple Myeloma
  
• High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse
  ClinicalTrials.gov Identifier: NCT00002630 - Active, not recruiting
  stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Safety and efficacy of single-agent CC-5013 in subjects with relapsed and refractory multiple myeloma
  ClinicalTrials.gov Identifier: NCT00065351 - Active, not recruiting
  Multiple Myeloma
  
• VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients with Previously Untreated Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00111319 - Active, not recruiting
  Multiple Myeloma
  
• Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00253578 - Recruiting
  Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma; Refractory Plasma Cell Neoplasm
  
• Chemotherapy, Vaccine Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00024466 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Study of Oral SCIO-469 in Relapsed, Refractory Patients with Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00087867 - Active, not recruiting
  Multiple Myeloma
  
• Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00004158 - Active, not recruiting
  stage II multiple myeloma; stage III multiple myeloma; stage I multiple myeloma; refractory plasma cell neoplasm
  
• Antineoplaston Therapy in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00003511 - Recruiting
  refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00021359 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Phase I/II Study of Safety & Efficacy of Perifosine & Bortezomib With or Without Dexamethasone for Multiple Myeloma Patients
  ClinicalTrials.gov Identifier: NCT00401011 - Recruiting
  Multiple Myeloma; Relapsed or Refractory Multiple Myeloma
  
• Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00002653 - Active, not recruiting
  Multiple Myeloma
  
• Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00004165 - Active, not recruiting
  refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; primary systemic amyloidosis
  
• A Multicenter, Open-Label, Single-Arm, Expanded Access Program For Lenalidomide Plus Dexamethasone In Previously Treated Subjects With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00179647 - Recruiting
  Multiple Myeloma
  
• Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Previously Untreated Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00002548 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients
  ClinicalTrials.gov Identifier: NCT00113919 - Active, not recruiting
  Multiple Myeloma
  
• Thal/Dex (Thalidomide and Dexamethasone) vs. Dd-T (Doxil, Dexamethasone and Thalidomide) in Multiple Myeloma Patients
  ClinicalTrials.gov Identifier: NCT00097981 - Active, not recruiting
  Multiple Myeloma
  
• Combination Chemotherapy, Peripheral Stem Cell Transplantation, Biological Therapy, Pamidronate and Thalidomide in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00004088 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients with Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00124813 - Recruiting
  Multiple Myeloma
  
• R115777 in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00021203 - Active, not recruiting
  stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Vincristine, DOXIL® (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00344422 - Active, not recruiting
  M-Protein; Multiple Myeloma; Myeloma; Myeloma Proteins
  
• Beta Alethine in Treating Patients With Myeloma
  ClinicalTrials.gov Identifier: NCT00006466 - Active, not recruiting
  monoclonal gammopathy of undetermined significance; stage I multiple myeloma; stage II multiple myeloma; extramedullary plasmacytoma; ...
  
• Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00483262 - Recruiting
  Multiple Myeloma; Relapsed Multiple Myeloma; Refractory Multiple Myeloma
  
• Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon alfa in Treating Patients With Advanced Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00006244 - Active, not recruiting
  refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Study of Combination Thalidomide Plus Glucocorticoid Therapy Versus Glucocorticoid Therapy Alone as Induction Therapy for Previously Untreated Subjects with Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00057564 - Active, not recruiting
  Multiple Myeloma
  
• Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00045136 - Active, not recruiting
  refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Phase I/II Study of hLL1 in Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00421525 - Recruiting
  Multiple Myeloma; Myeloma, Plasma-Cell; Plasmacytoma
  
• Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combination with DTPACE Chemotherapy and Autologous Transplantation in Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00090493 - Recruiting
  Multiple Myeloma
  
• Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00084747 - Recruiting
  stage II multiple myeloma; stage III multiple myeloma
  
• Bortezomib in Treating Patients With Newly Diagnosed High-Risk Stage III Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00075881 - Active, not recruiting
  stage III multiple myeloma
  
• Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00003146 - Completed
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects with Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00056160 - Active, not recruiting
  Multiple Myeloma
  
• Study of DOXIL/CAELYX and VELCADE or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00103506 - Active, not recruiting
  Multiple Myeloma
  
• Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00151203 - Active, not recruiting
  Multiple Myeloma
  
• Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00112879 - Recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00316940 - Active, not recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00186238 - Active, not recruiting
  Multiple Myeloma
  
• Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells
  ClinicalTrials.gov Identifier: NCT00186316 - Active, not recruiting
  Multiple Myeloma
  
• Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Combination with Bortezomib in Patients with Advanced Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00111813 - Recruiting
  Multiple Myeloma
  
• Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00317811 - Active, not recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00046852 - Active, not recruiting
  Infection; refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
  ClinicalTrials.gov Identifier: NCT00257114 - Active, not recruiting
  Multiple Myeloma
  
• Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00028886 - Active, not recruiting
  stage II multiple myeloma; stage III multiple myeloma
  
• Bortezomib (Velcade) in Patients with Untreated Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00153920 - Active, not recruiting
  Multiple Myeloma
  
• The Optimal Timing of a Second Autologous Peripheral Blood Stem Cell Transplantation in Patients (<61 Years) With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00207805 - Active, not recruiting
  Multiple Myeloma
  
• A Multicentre, Single-Arm, Open-Label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00420849 - Active, not recruiting
  Multiple Myeloma
  
• Stem Cell Transplantation in Treating Patients With Previously-Treated Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00054353 - Recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00227682 - Active, not recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00193557 - Active, not recruiting
  Multiple Myeloma
  
• Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients
  ClinicalTrials.gov Identifier: NCT00327249 - Active, not recruiting
  Multiple Myeloma
  
• Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients
  ClinicalTrials.gov Identifier: NCT00382694 - Active, not recruiting
  Multiple Myeloma
  
• Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.
  ClinicalTrials.gov Identifier: NCT00388635 - Active, not recruiting
  Multiple Myeloma
  
• Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00014339 - Active, not recruiting
  stage II multiple myeloma; stage III multiple myeloma; Quality of Life
  
• FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00066638 - Active, not recruiting
  stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• UARK 2003-41: A Study of High-Dose Density Therapy in Patients with Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00113932 - Active, not recruiting
  Multiple Myeloma
  
• A Phase I Study of DVd +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)
  ClinicalTrials.gov Identifier: NCT00091624 - Active, not recruiting
  Multiple Myeloma
  
• Safety Study of IPI-504 in Patients with Relapsed and Relapsed Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00113204 - Active, not recruiting
  Multiple Myeloma
  
• Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00116961 - Active, not recruiting
  Multiple Myeloma
  
• A Pilot Study of Combination Therapy with VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00135187 - Active, not recruiting
  Multiple Myeloma
  
• Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy
  ClinicalTrials.gov Identifier: NCT00004040 - Active, not recruiting
  stage II chronic lymphocytic leukemia; stage I multiple myeloma; stage II multiple myeloma; stage IV chronic lymphocytic leukemia; ...
  
• Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00028600 - Recruiting
  refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00478777 - Active, not recruiting
  Relapsed or Refractory Multiple Myeloma
  
• Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00193544 - Active, not recruiting
  Multiple Myeloma
  
• Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00256880 - Active, not recruiting
  Multiple Myeloma
  
• Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00375791 - Active, not recruiting
  Multiple Myeloma
  
• Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00263484 - Recruiting
  Multiple Myeloma
  
• Arsenic Trioxide in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00017433 - Active, not recruiting
  stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients with Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00039754 - Active, not recruiting
  Multiple Myeloma
  
• An Invstigational Drug, PD 0332991, is Being Studied in Combination With Velcade and Dexamethasone in Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment for Multiple Myeloma.
  ClinicalTrials.gov Identifier: NCT00555906 - Not yet recruiting
  Multiple Myeloma
  
• Comparison Between FDG-PET and MRI for the Assessment of Response to Intensive Chemotherapy in Multiple Myeloma Patients.
  ClinicalTrials.gov Identifier: NCT00200668 - Not yet recruiting
  Multiple Myeloma
  
• Study of Combination PS-341 and Thalidomide in Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00083460 - Active, not recruiting
  Multiple Myeloma
  
• Stem Cell Transplant for Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00386568 - Active, not recruiting
  Multiple Myeloma